Pacific Biosciences of California Inc (PACB) is now in the Fair zone, suggesting that its current forward PS ratio of 3.24 is considered Fairly compared with the five-year average of -9.17. The fair price of Pacific Biosciences of California Inc (PACB) is between 0.46 to 10.43 according to relative valuation method.

Relative Value

Fair Zone

0.46-10.43

Current Price：1.58

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Pacific Biosciences of California Inc (PACB) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Pacific Biosciences of California Inc (PACB) has a current Price-to-Book (P/B) ratio of 15.39. Compared to its 3-year average P/B ratio of 3.95, the current P/B ratio is approximately 289.61% higher. Relative to its 5-year average P/B ratio of 5.90, the current P/B ratio is about 160.91% higher. Pacific Biosciences of California Inc (PACB) has a Forward Free Cash Flow (FCF) yield of approximately -22.73%. Compared to its 3-year average FCF yield of -31.56%, the current FCF yield is approximately -27.99% lower. Relative to its 5-year average FCF yield of -21.63%, the current FCF yield is about 5.09% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for PACB competitors is 2.38, providing a benchmark for relative valuation. Pacific Biosciences of California Inc Corp (PACB.O) exhibits a P/S ratio of 3.24, which is 36.44% above the industry average. Given its robust revenue growth of 13.82%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of PACB increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of PACB in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is PACB currently overvalued or undervalued?

What is Pacific Biosciences of California Inc (PACB) fair value?

PACB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Pacific Biosciences of California Inc (PACB) is between 0.46 to 10.43 according to relative valuation method.

How does PACB's valuation metrics compare to the industry average?

The average P/S ratio for PACB's competitors is 2.38, providing a benchmark for relative valuation. Pacific Biosciences of California Inc Corp (PACB) exhibits a P/S ratio of 3.24, which is 36.44% above the industry average. Given its robust revenue growth of 13.82%, this premium appears unsustainable.

What is the current P/B ratio for Pacific Biosciences of California Inc (PACB) as of Mar 02 2026?

As of Mar 02 2026, Pacific Biosciences of California Inc (PACB) has a P/B ratio of 15.39. This indicates that the market values PACB at 15.39 times its book value.

What is the current FCF Yield for Pacific Biosciences of California Inc (PACB) as of Mar 02 2026?

As of Mar 02 2026, Pacific Biosciences of California Inc (PACB) has a FCF Yield of -22.73%. This means that for every dollar of Pacific Biosciences of California Inc's market capitalization, the company generates -22.73 cents in free cash flow.

What is the current Forward P/E ratio for Pacific Biosciences of California Inc (PACB) as of Mar 02 2026?

As of Mar 02 2026, Pacific Biosciences of California Inc (PACB) has a Forward P/E ratio of -3.33. This means the market is willing to pay $-3.33 for every dollar of Pacific Biosciences of California Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Pacific Biosciences of California Inc (PACB) as of Mar 02 2026?

As of Mar 02 2026, Pacific Biosciences of California Inc (PACB) has a Forward P/S ratio of 3.24. This means the market is valuing PACB at $3.24 for every dollar of expected revenue over the next 12 months.

PACB Valuation